NICE draft guidance recommends pertuzumab for early treatment of breast cancer
NICE has published guidance recommending pertuzumab (Perjeta, Roche) for treating early HER2-positive breast cancer in people whose disease has spread to their lymph nodes.
Source: NHS Networks - Category: UK Health Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | National Institute for Health and Clinical Excelle | UK Health